Shin D, et al. World J Mens Health. 2024 Jan;42(1):229-236. https://doi.org/10.5534/wjmh.230172

Sarcopenia is a condition characterized by a progressive loss of muscle mass and function which are influenced by certain factors such as aging, nutritional deficiencies, and chronic diseases. Despite numerous efforts to prevent or treat sarcopenia, effective therapeutic options for this disease remain limited. This study aims to evaluate the effects of KGC01CE treatment, a mixture of Cervus elaphus (Ce) and Eucommia ulmoides (Eu), which are well-known traditional herbal medicines in Asia, on age-related muscle loss and functional decline in aged rats. KGC01CE has been found to be more effective than the individual extracts in inhibiting dexamethasone (DEX)-induced muscle atrophy and improving muscle mass and grip strength in C2C12 cells and aged rats. Moreover, animal studies were conducted to determine the minimum effective dose, and a 12-week oral administration of KGC01CE treatment at doses of 50, 100, and 200 mg/kg to 15-month-old aged rats resulted in a dose-dependent increase in lean mass, muscle mass, grip strength, and muscle cross-sectional area (CSA), which had decreased due to aging. Furthermore, it was shown that KGC01CE activated the phosphatidylinositol 3-kinase (PI3K)/Akt pathway and inhibited the expression of muscle-degrading proteins MuRF, Atrogin-1, and myostatin. These results suggest that KGC01CE treatment may effectively prevent muscle loss and functional decline, providing a novel therapeutic strategy for sarcopenia.

Panax ginseng Meyer of the Araliaceae family have various biological activities and pharmacological actions such as anticancer, immunomodulation, and anti-inflammatory. In many studies on ginseng, studies on ginseng fruit are still new, and the effect and potential of ginseng fruit on periodontitis in HPDL cells have been investigated in vitro and in vivo. HPDL cells were stimulated with PG-LPS for 12 h to evaluate the effects of KGC19b (50–200 μg/mL) on periodontitis. Cell viability, pro-inflammatory markers, reactive oxygen species (ROS), and osteogenesis-related markers were assessed. In the rat model, periodontitis was induced using ligature and PG-LPS, and KGC19b was administered orally for 6 days. The effects of KGC19b were evaluated by micro-CT analysis and H&E staining. KGC19b reduced pro-inflammatory cytokine expression, restored osteogenic markers, enhanced antioxidant enzyme activity, and decreased ROS in HPDL cells. In the rat model, KGC19b alleviated periodontal inflammation and prevented bone mass loss. In this study, KGC19b shows the possibility of improving and treating periodontitis through anti-inflammatory, osteogenesis, and antibacterial effects.